Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 4/20 | 0.44 |
| ▸ | CA1 | P00915 | 4/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CA7 | P43166 | 2/20 | 0.44 |
| ▸ | CA9 | Q16790 | 2/20 | 0.44 |
| ▸ | TACR1 | P25103 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19356374 | 1.00 | KMT2A (0.49) | KMT2ARCE1TSHRHTTCA1 | |
| SCHEMBL20009805 | 0.89 | RCE1 (0.47) | KMT2ARCE1TSHRHTTCA1 | |
| SCHEMBL23278063 | 0.84 | CA1 (0.49) | KMT2ARCE1TSHRHTTCA1 | |
| SCHEMBL22113525 | 0.84 | KMT2A (0.47) | KMT2ARCE1TSHRHTTCA1 | |
| SCHEMBL14461636 | 0.83 | RCE1 (0.49) | RCE1TSHRHTT | |
| SCHEMBL10974138 | 0.83 | TSHR (0.41) | KMT2ARCE1TSHRHTTCA1 | |
| SCHEMBL23989405 | 0.81 | KMT2A (0.45) | KMT2ARCE1TSHRHTTCA1 | |
| SCHEMBL19592305 | 0.81 | CA1 (0.46) | KMT2ARCE1TSHRHTTCA1 | |
| SCHEMBL23340707 | 0.81 | TSHR (0.40) | KMT2ARCE1TSHRHTTCA1 | |
| SCHEMBL22113526 | 0.81 | KMT2A (0.57) | KMT2ATSHRHTTCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230045939-A1 | STABLE VACCINE AGAINST CLOSTRIDIUM DIFFICILE | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-02-16 | — | — | US | disclosed |
| EP-2896397-B2 | Novel compounds having inhibitory activity against sodium-dependant glucose transporter | MITSUBISHI TANABE PHARMA CORP (JP) | 2020-10-07 | — | — | EP | disclosed |
| WO-2017156508-A1 | C-GLYCOSIDE COMPOUNDS USEFUL FOR TREATING DISEASE | FIMBRION THERAPEUTICS, INC. (US) | 2017-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230045939-A1 | STABLE VACCINE AGAINST CLOSTRIDIUM DIFFICILE | DDOST, SI, CD4 | KMT2A 3476/4885RCE1 1094/4885TSHR 3529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.